We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Teva Suit Built On 'Tottering Tower Of Conjecture,' FDA Says

Law360 (November 5, 2018, 6:47 PM EST) -- Teva Pharmaceuticals’ high-profile challenge to a new U.S. Food and Drug Administration policy on generic-drug exclusivity is wildly speculative and has virtually no chance of succeeding, the FDA told a D.C....
To view the full article, register now.




Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only


District Of Columbia

Nature of Suit

Administrative Procedure Act/Review or Appeal of Agency Decision

Date Filed

October 17, 2018

Law Firms


Government Agencies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.